Company News & Press
23 September 2020
New and existing investors contributed to biotech’s largest ever capital raise; company also announced appointment of Robert A. Cascella, Chief Business Leader, Precision Diagnostics, and Executive Vice President of Phillips, as one of three independent members of the Metabolon Board of Directors.
Metabolon will perform metabolomics on study participants as part of the five-year longitudinal study to improve risk assessment of complications of obesity, supporting greater understanding in patient stratification for the right treatment depending on metabolic profiles.
Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.
Find Us at These Events
23 September 2020
September 23rd 7:00 am EDT/13:00 CEST Across the globe, 37.9 million people are living with HIV (PLWH). With access to...
21 September 2020
Visit us at booth 610 Connect with 2000+ global scientists, engineers and executives working across the entire spectrum of biopharmaceutical development and production.
14 September 2020
September 14th 12:00 pm EDT Metabolomics offers researchers the ability to get closer to the phenotype by identifying small molecules...
IGES is the International Genetic Epidemiology Society, a scientific society concerned with “the study of genetic components in complex biological phenomena” according to James V. Neel, the founding President of the Society. The successful mapping of the human genome will greatly facilitate the study of health and disease in a manner that integrates both host and environmental factors.
27 May 2020
Join Metabolon’s Patricia Sheridan, Ph.D., Senior Study Director, Discovery & Translational Sciences, for a conversation with Dr. Heath on May 27th at 11:00 am EDT/13:00 CEST. They will be discussing some of the current work that ISB is doing to explore COVID-19 infections and how metabolomics can be used to understand the pathophysiology of the infection.